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https://doi.org/10.1016/j.celrep.2020.107761SUMMARYVitamin-D-binding protein (DBP) or group-specific component of serum (GC-globulin) carries vitamin D me-
tabolites from the circulation to target tissues. DBP is highly localized to the liver and pancreatic a cells.
Although DBP serum levels, gene polymorphisms, and autoantigens have all been associated with diabetes
risk, the underlying mechanisms remain unknown. Here, we show that DBP regulates a cell morphology, a
cell function, and glucagon secretion. Deletion of DBP leads to smaller and hyperplastic a cells, altered
Na+ channel conductance, impaired a cell activation by low glucose, and reduced rates of glucagon secretion
both in vivo and in vitro. Mechanistically, this involves reversible changes in islet microfilament abundance
and density, as well as changes in glucagon granule distribution. Defects are also seen in b cell and d cell
function. Immunostaining of human pancreata reveals generalized loss of DBP expression as a feature of
late-onset and long-standing, but not early-onset, type 1 diabetes. Thus, DBP regulates a cell phenotype,
with implications for diabetes pathogenesis.INTRODUCTION
Vitamin-D-binding protein (DBP), a 52- to 59-kDa protein also
known as group-specific component of serum (GC-globulin), is
the primary plasma carrier for circulating vitamin D and its metab-
olites (White and Cooke, 2000). GC/Gc, which encodes DBP, is
present in the liver ofallmammals (Feldmanetal., 2017), in keeping
with the functionof this organ to convert sterol derivatives, suchas
cholecalciferol (vitamin D3) into pre-hormone 25-OH vitamin D
(25(OH)D) (Bikle, 2014). DBP is also localized to the pancreatic is-
lets. Recent studies have shown thatGC/Gc is highly expressed in
purified mouse and human a cells (Ackermann et al., 2016;
Adriaenssens et al., 2016; Cigliola et al., 2018; Qiu et al., 2017; Se-
gerstolpeetal., 2016) and isupregulated inde-differentiatedbcells
(Kuo et al., 2019). Because the GC promoter region contains cell-
type-selective open chromatin regions,GC can be classified as an
a cell signature gene, similarly to prototypical hits, such as ARX,
glucagon (GCG), IRX2, and DPP4 (Ackermann et al., 2016; Lam
et al., 2019). Despite these findings, the role of DBP in the regula-
tion of islet function and glucagon release remains enigmatic.This is an open access article undEvidence that the effects of DBP in a cells are unrelated to
serum vitamin D transport comes from studies in vitamin-D-defi-
cient patients who show no improvement in insulin-induced
glucagon output upon vitamin D repletion (Gedik and Akalin,
1986). Moreover, a patient harboring a rare mutation in GC
showed no symptoms of vitamin D deficiency, despite low
plasma levels of 25(OH)D, arguing that the free form of 25(OH)
D dictates many of the non-classical actions of vitamin D
(Chun et al., 2014; Henderson et al., 2019). Alongside its role in
25(OH)D transport, DBP is also a major actin scavenger (Harper
et al., 1987). Following disassembly of polymerized F-actin by
gelsolin, DBP trapsmonomeric filaments using its three domains
as a clamp (Otterbein et al., 2002). Pertinently, ephrin-A forward
signaling has been shown to inhibit glucagon secretion through
increases in F-actin density (Hutchens and Piston, 2015), and
the appearance of regulated glucagon secretion in re-aggre-
gated islets coincides with normalization of F-actin levels (Reis-
saus and Piston, 2017).
Linking DBP with type 2 diabetes (T2D) risk, GC variants are
associated with elevations in fasting glucose, fasting insulinCell Reports 31, 107761, June 16, 2020 ª 2020 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Phenotypic Assessment of DBP/ Mice
(A) Representative fluorescence immunohistochemistry image showing localization of DBP to a cells and its specific loss in DBP/ animals (scale bar represents
34 mm, top and middle panels; scale bar represents 12 mm, bottom panel; n = 3 to 4 animals).
(B) As for (A), but non-fluorescent DAB staining in DBP+/+ and DBP/ pancreatic sections (scale bar represents 40 mm; the middle and last panel are magnified
relative to the first panel; n = 2 to 3 animals).
(C) Fluorescence immunohistochemistry showing DBP staining of b cells, which is absent in pancreatic sections fromDBP/ animals. Due to the relative strength
of DBP expression in a cells, the images have been overexposed to allow visualization of DBP in the non-a-cell compartment (representative images are shown;
scale bar represents 85 mm; n = 13 islets, 3 animals).
(D) Expression of Gc, which encodes DBP, is barely detectable in DBP/ islets using Taqman assays (n = 4 to 5 animals).
(E and F) Serum 25(OH)D (E) and 1,25(OH)2D (F) levels are 2-fold and 4-fold lowered in DBP+/ and DBP/ animals, respectively (n = 4–6 animals; one-way
ANOVA with Bonferroni’s multiple comparisons test).
(G and H) Glucose tolerance curves (G) and area under the curve (AUC) (H) are similar in DBP+/+ and DBP/mice (n = 7–11 animals; two-way repeated-measure
ANOVA with Bonferroni’s multiple comparison test or unpaired t test).
(I) Pyruvate tolerance is similar in DBP+/+ and DBP/mice (n = 3 to 4; two-way repeated-measure ANOVAwith Bonferroni’s multiple comparison test or unpaired
t test).
(J and K) Insulin sensitivity tends to be increased in DBP/ versus DBP+/+ mice (J), as also shown by the AUC (K) (n = 12 animals; two-way repeated-measure
ANOVA with Bonferroni’s multiple comparisons test or unpaired t test).
(L) % decrease in glucose is greater in DBP/ versus DBP+/+ mice 30 min post-insulin injection (n = 12 animals; two-way ANOVA with Fisher’s least significant
difference [LSD]).
(M) Glucagon secretion in response to insulin bolus is impaired in DBP/ mice (n = 5 animals; two-way ANOVA with Bonferroni’s multiple comparisons test).
(legend continued on next page)
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OPEN ACCESSlevels, and impaired responses to oral glucose challenge (Baier
et al., 1998; Hirai et al., 2000; Iyengar et al., 1989; Szathmary,
1987). Results, however, tend to be conflicting, likely reflecting
heterogeneity introduced by ethnicity and environment (Malik
et al., 2013; Wang et al., 2014). The concept that DBP might
also be involved in type 1 diabetes (T1D) risk is supported by
retrospective cross-sectional analysis of 472 individuals
showing that serum DBP levels were lowest in patients with
T1D (Blanton et al., 2011). Using gene-expression-based
genome-wide association studies, DBP was subsequently iden-
tified as a novel T1D autoantigen (Kodama et al., 2016). The
same authors showed that T cell reactivity against DBP was
increased in non-obese diabetic mice and that humans with
T1D possess specific DBP autoantibodies (Kodama et al.,
2016). Together, these studies suggest that DBP is likely to be
associated with altered diabetes risk in humans.
Here, we sought to establish the role of DBP in a cell pheno-
type, function, and diabetes risk by combining studies in
knockout mice with immunostaining analysis of pancreata from
T1D donors and age-matched controls. We show that DBP con-
tributes to proper a cell function and glucagon secretion, with
related effects for d cell morphology and insulin release. We
further show that glucagon and DBP expression decrease in a
cells of individuals with late-onset or long-standing T1D, but
not in those with early-onset disease. As such, DBP should be
considered as an essential component of the a cell and the wider
islet functional machinery with relevance for glucagon secretion
during diabetes.
RESULTS
DBP Is Deleted in a Cells of DBP/ Mice
Mice possessing floxed Gc alleles do not exist, so we instead
turned to awell-validated global DBP/ knockout model (Safadi
et al., 1999). Given the localization of DBP to a cells and liver, as
well as the existence of a patient with a loss-of-function DBPmu-
tation (Henderson et al., 2019), we reasoned that the global
DBP/ knockout model would be most appropriate for our
purposes.
Confocal imaging showed an intense DBP signal localized
predominantly to GCG+ cells at the islet periphery in mice (Fig-
ure 1A). Although DBP expression was clearly decreased in
DBP/ animals (% area DBP expression = 10.75% ± 2.05%
versus 1.60% ± 0.36%, DBP+/+ versus DBP/, respectively;
p < 0.01; Mann-Whitney test), a very faint signal could still be de-
tected in the cytoplasm of some a cells using fluorescent immu-
nohistochemistry (Figure 1A). This likely reflects the sensitivity of
the fluorescent staining rather than antibody specificity, because
we could not detect any DBP signal in DBP/ islets with the
same antibody using an enzymatically amplified chromogenic(N) Body weight/growth curve is similar in DBP+/+ and DBP/mice (n = 3 to 4; two
unpaired t test).
(O) Gctm1.1(KOMP)Vlcg mice with homozygous loss ofGc (mut) present with decreas
males and 6Gc-null females versus 666male and 654 female controls; MixedMod
classified equally). Data were obtained from the International Mouse Phenotypin
ID = MGI:95669, data release 11.
Bar and line graphs showmean ± SEM. *p < 0.05, **p < 0.01, and NS, non-significanstaining (Figure 1B). We wondered whether DBP was also ex-
pressed in other islet cell types but might be obscured by the
strong staining detected in a cells. Therefore, immunostaining
was repeated using a higher antibody concentration combined
with more sensitive imaging settings to oversaturate signal in a
cells, but not in other cells. Using this approach, weak DBP
expression could be detected in the b cell compartment, which
was absent in islets from DBP/ mice (Figure 1C).
Gc expression was found to be 80% lower in DBP/ islets
using specific Taqman assays (Figure 1D), and circulating
25(OH)D and hormonal 1,25-(OH)2 vitamin D (1,25(OH)2D) levels
were50%decreased in heterozygous DBP+/mice and almost
at the limit of detection in homozygous DBP/ littermates (Fig-
ures 1E and 1F). Despite low levels of 25(OH)D and 1,25(OH)2D,
DBP/ animals did not show signs of vitamin D deficiency un-
less placed on a vitamin-D-deficient diet (Safadi et al., 1999).
Altogether, we can be confident that DBP is deleted in our cohort
of DBP/ animals.
DBP/ Mice Secrete Less Glucagon
Metabolic phenotyping of 8- to 12-week-old DBP/ mice re-
vealed normal glucose tolerance (Figures 1G and 1H) and normal
pyruvate tolerance versus littermate controls (Figure 1I). How-
ever, DBP/ animals tended to possess improved insulin sensi-
tivity (Figures 1J and 1K), which was significant when the per-
centage change versus baseline was considered at 30 min
(Figure 1L). These changes in insulin tolerance were accompa-
nied by robust decreases in glucagon secretion in DBP/
versus DBP+/+ littermates (Figure 1M). Growth curves and adult
body weight were similar between genotypes (Figure 1N). We
next interrogated International Mouse Phenotyping Consortium
data pertaining to Gctm1.1(KOMP)Vlcg mice, which also harbor
whole-body deletion of DBP (MGI:5577272). Notably, mutant
Gctm1.1(KOMP)Vlcg mice showed highly significant decreases in
fed blood glucose (Figure 1O), consistent with lowered circu-
lating glucagon (Brand et al., 1995).
Thus, DBP/mice are more insulin sensitive and secrete less
glucagon than their DBP+/+ littermates. To confirmwhether these
changes were associated with impaired a cell function, we pro-
ceeded to conduct the remainder of the studies in isolated pan-
creata and islets.
Deletion of DBP Leads to Abnormal Islet Morphology
Cell resolution immunostaining of entire pancreatic sections
showed no changes in a cell or b cell mass following loss of
DBP (Figures 2A and 2B). Although detailed morphometric ana-
lyses of individual DBP/ islets revealed an increase in a cell
number (Figures 2C and 2D), this was accompanied by a
decrease in a cell size (Figure 2E), maintaining the area occupied
by a cells (Figure 2F). While a small but significant increase in b-way repeated-measure ANOVA with Bonferroni’s multiple comparison test or
es in fed blood glucose compared to controls (con) (n = 7 homozygous Gc-null
el framework, linear mixed-effects model, equation without weight; both sexes
g Consortium (https://www.mousephenotype.org; Dickinson et al., 2016), MGI
t. DAB, 3,30-diaminobenzidine; DBP, vitamin D-binding protein; GCG, glucagon.
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Figure 2. DBP Alters a Cell and d Cell Number and Size
(A and B) Cell resolution reconstruction of pancreatic sections reveals no differences in a cell and b cell mass in DBP+/+ and DBP/ mice (A), quantified in bar
graph (B) (scale bar represents 530 mm; representative images are shown; inset is a zoom showing maintenance of cellular resolution in a single image; n = 9–12
sections from 3 to 4 animals; unpaired t test).
(C–I) Morphological analyses of DBP/ islets (C) reveal increased a cell number (D) and decreased a cell size (E) (representative images shown in right panel), but
normal area occupied (F). By contrast, b cell number is increased (G), although b cell size (H) (representative images shown in right panel) and area (I) are un-
changed (scale bar in D represents 85 mm; scale bars in E and H represent 10 mm; n = 24–45 islets from 3 to 4 animals; E andH are zooms of C to better show a cell
and b cell size; DAPI is shown in blue; unpaired t test).
(J–M) d cell proportion (J and K; n = 55–79 islets from 4 to 5 animals) and size (L andM; n = 29 to 30 islets from 3 animals) are decreased in DBP/ islets (scale bar
in J represents 85 mm; scale bar in L represents 10 mm; representative images are shown; L is a zoom of J to better show d cell size; unpaired t test).
(N) Expression levels of the a cell differentiation markers Arx, Pax6, Pou3f4, and Irx2 are similar in DBP+/ and DBP/ islets (n = 3–10 animals; Mann-Whitney
test). Note that Arx, Pax6, and Pou3f4were quantified using SYBR Green chemistry, whereas Irx2was quantified using Taqman reagents. For the sake of clarity,
all genes are presented on the same graph normalized to their respective housekeeping gene.
(O–Q) No changes in the proportion of a cells expressing PDX1 (O and P) orMAFA (O andQ) are detected in pancreatic sections fromDBP/ versus DBP+/+ islets
(scale bar represents 85 mm; representative images are shown; n = 17–27 islets from 3 animals; unpaired t test).
(legend continued on next page)
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OPEN ACCESScell number was apparent (Figure 2G), no changes in b cell size
(Figure 2H) or area occupied by b cells (Figure 2I) were detected
between DBP/ and DBP+/+ animals. However, a 50%
decrease in d cell mass was detected (Figures 2J and 2K), along
with a reduction in the size of individual d cells (Figures 2L
and 2M).
Suggesting that loss of DBP is not associated with a cell de-
differentiation, mRNA levels for Pax6, Arx, Pou3f4, and Irx2
were similar in islets from DBP+/+ and DBP/ mice (Figure 2N).
No differences in the number of (very rare) cells co-staining for
GCG/PDX1 or GCG/MAFA were detected (Figures 2O–2Q),
implying that adoption of a b-cell- or d-cell-like fate by a cells
was unlikely. Although DBP was expressed in some, but not
all, d cells (37.8% ± 12.9%; mean ± SD; Figure 2R), expression
of the d cell markers Hhex and Ghsr was unchanged in DBP/
islets (Figure 2S). Lastly, a similar number of proliferating cell nu-
clear antigen (PCNA)+ or proliferative a cells was detected in
DBP/ and DBP+/+ animals, suggesting normal cell turnover
rates (Figure S1).
Thus, DBP/ islets are morphologically abnormal, containing
smaller and more abundant a cells alongside a modest contrac-
tion of the d cell compartment.
DBP Contributes to a Cell, d Cell, and b Cell Function
Multicellular Ca2+ imaging of DBP/ islets showed large impair-
ments in the activity of a cells, identified by their responses to low
glucose (0.5mM) and epinephrine (Figures 3A–3C) or silencing at
high (17 mM) glucose (Tian et al., 2011). This presented as a loss
of a cell activation by low glucose (Figure 3A; Videos S1 and S2),
although some a cells that remained active displayed character-
istic Ca2+-spiking responses of elevated amplitude (Figures 3B
and 3C).
The same islets were also examined for changes in b cell ac-
tivity at both low (0.5 mM) and high (17 mM) glucose. A large in-
crease in the proportion of b cells active at low glucose was
observed (Figure 3D), identified on the basis of their responsive-
ness to subsequent challenge with high glucose. However, no
differences in b cell activity were detected at high glucose (Fig-
ure 3E), suggesting the presence of intact glucose metabolism.
Gene expression analyses showed no significant changes in
levels of the b cell transcription factors Pdx1, Mafa, Nkx6-1, as
well as Ins1 and Ins2 (Figure 3F).
To record d cell activity, islets were imaged at 5 mM glucose
before increasing concentration of the sugar to 17 mM. d cells
are identified by their characteristic, rare, Ca2+-spiking patterns
at 5 mM glucose, which are maintained in the presence of high
glucose (compared to b cells and a cells that are inactive at
5 mM and 17 mM, respectively; Shuai et al., 2016; Vierra et al.,
2018). Suggesting the presence of abnormal function, the pro-
portion of active d cells was increased in DBP/ islets (Figures
3G and 3H; Videos S3 and S4), possibly reflecting compensation
for reduced d cell number. Responsive d cells displayed Ca2+
spikes of normal amplitude (Figure 3I). Although the number of(R) DBP is expressed in a subpopulation of d cells (arrows show SST+/DBP+ cell
(S) The d cell markers Hhex and Ghsr are not significantly different in DBP/ isle
test).
Bar graphs show scatterplot with mean ± SEM. *p < 0.05 and **p < 0.01. INS, ina cells active at low (0.5 mM) glucose was also increased in
DBP/ islets, these cells would be silent at high glucose, thus
allowing their differentiation from d cells.DBP Is Required for Normal a Cell Na+ Channel
Conductance
As part of a cell electrical activity, Na+ channel inactivation prop-
erties play an important role in determining glucagon secretion
(Zhang et al., 2013). Using patch-clamp electrophysiology, we
therefore explored whether DBP influences a cell Na+ channel
function. As expected from the increased Ca2+ amplitude de-
tected in these cells, Na+ currents were increased in a cells lack-
ing DBP (Figures 3J and 3K). The slope factor of Na+ inactivation
also tended to be increased (Figures 3L and 3M), despite a
similar half-maximal voltage (Figure 3N), suggesting the pres-
ence of impairments in glucose-dependent a cell activity.
We further subjected patch-clamp recordings from DBP+/+
and DBP/ islets to a mathematical model (Briant et al.,
2017). This model takes as input the electrophysiological data
of a cell and outputs a probability that the cell is an a cell.
Although the model predicted a cell phenotype in DBP+/+ islets
with high probability, confidence was lower in recordings from
DBP/ islets with the output favoring a more d-cell-like (proba-
bility = 0.27 versus 0.48, DBP+/+ versusDBP/, respectively; p <
0.05), but not b-cell-like (probability = 4.433 107 versus 1.153
108, DBP+/+ versus DBP/, respectively; non-significant), pro-
file (Figure 3O). Thus, a cells lose their ‘‘electrophysiological
identity,’’ become less a cell like, and resemble d cells following
loss of DBP. This alteration in phenotype would not be expected
to interfere with the identification of a cells using Ca2+ imaging,
because epinephrine was used to differentiate a cells, b cells,
and d cells. In any case, the change in proportion of cells active
at low glucose supports the finding here that a cells lose their
phenotype. Confirming the decrease in a cell size detected using
immunohistochemistry, membrane capacitance was signifi-
cantly lower in cells predicted to be a cells in DBP/ islets
(Figure 3P).DBP Regulates Glucagon and Insulin Secretion
DBP+/+ islets responded to low (0.5 mM) glucose with a 2-fold in-
crease in glucagon secretion (Figures 3Q and 3R). By contrast,
DBP/ islets showed a tendency toward increased basal
glucagon levels and loss of glucagon secretion in response to
low glucose (Figures 3Q and 3R). Glucagon secretory responses
to epinephrine were also significantly impaired in DBP/ islets,
pointing toward a defect in either adrenergic receptor signaling
or exocytosis (Figures 3Q and 3R). This defect is unlikely to be
associated with altered electrical signaling, because epinephrine
does not influence membrane potential (Hamilton et al., 2018).
Suggesting the presence of normal glucagon biosynthesis, total
levels of the hormone were similar between DBP+/+ and DBP/
littermates (Figure 3S).s; n = 3 animals; scale bar represents 85 mm).
ts (n = 8–10 animals; one-way ANOVA with Bonferroni’s multiple comparisons
sulin; SST, somatostatin. See also Figure S1.
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Figure 3. Dysregulated a cell, b cell, and d cell Function in Islets Lacking DBP
(A and B) Proportion of a cells showing activityat low (0.5 mM) glucose is decreased in DBP/ islets (A), although Ca2+ amplitude is increased in responsive cells
(B) (n = 46–30 islets, 4 animals; Mann-Whitney test).
(C) Representative images and traces showing loss of a cell activation in DBP/ islets (scale bar represents 40 mm; n = 46–30 islets, 4 animals).
(D and E) Proportion of b cells showing activity at low (0.5 mM; D) glucose is increased in DBP/ islets, despite intact responses to high (17 mM) glucose (E),
shown by bar graph and traces (n = 27–29 islets, 4 animals; unpaired t test). Note that error bars (SD) are shown above (DBP/) and below (DBP+/+) traces so as
not to obscure the mean.
(F) Expression of Pdx1, Mafa, Nkx6-1, Ins1, and Ins2 is not significantly different between DBP/ and DBP+/+ islets (4–6 animals; paired t test).
(G–I) More d cells are active at 5mMglucose in DBP/ compared toDBP+/+ islets (G andH), mounting Ca2+ spikeswith a tendency toward increased amplitude (I)
(representative Ca2+ images and traces are shown; images have been cropped to show a single islet; scale bar represents 40 mm; n = 28 to 29 islets, 4 animals;
unpaired t test).
(J and K) Representative patch-clamp recordings of a cells (J) showing increased Na+ conductance in DBP-/- islets (K) (n = 17–22 cells, 3 animals; unpaired t test).
(L–N) Sigmoid plots of raw current data showing calculation of slope factor and half-maximal voltage (V1/2) for two cells (L). Summary data show a tendency
toward increased slope factor for Na+ channel inactivation (M) but unchanged half-maximal voltage (N) in DBP/ versus DBP+/+ a cells (n = 17–22 cells, 3
animals; Mann-Whitney test).
(O) Electrophysiological fingerprinting reveals decreased and increased probability of cells resembling an a cell or d cell, respectively, in DBP/ islets (n = 17–22
cells, 3 animals; Mann-Whitney test).
(P) a cell capacitance is significantly reduced in DBP/ islets (n = 17–22 cells, 3 animals; unpaired t test).
(Q and R) Glucagon secretion is impaired in DBP/ islets in response to low (0.5 mM) glucose and low (0.5 mM) glucose + epinephrine, shown normalized to
content (Q) or fold-change (R) (n = 12–14 replicates, 10 animals; two-way ANOVA with Bonferroni’s multiple comparisons test or Mann-Whitney test).
(S) Glucagon content is similar in DBP+/+ and DBP/ islets (n = 12 replicates, 8 animals; unpaired t test).
(T and U) Insulin secretion in response to high (17mM) glucose or high (17mM) glucose + KCl is increased in DBP/ islets, shown normalized to content (T) or fold
change (U) (n = 11–13 replicates, 3 animals; two-way ANOVA with Bonferroni’s multiple comparisons test or unpaired t test).
(V) Insulin content is similar in DBP+/+ and DBP/ islets (n = 14 replicates, 3 animals; unpaired t test).
Bar graphs show scatterplot with mean ± SEM. Traces show mean ± SD. *p < 0.05 and **p < 0.01.
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Figure 4. DBP Scavenges Actin in the Islet and Maintains Glucagon
Granule Morphology
(A–C) F-actin abundance is increased following loss of DBP (A), quantified
using fluorescence intensity (B) and fiber density (C) (representative images
are shown; scale bar represents 53 mm; n = 23 islets, 3 animals; unpaired
t test).
(D and E) As for (A)–(C) but representative images (D) and summary bar graph
(E) showing decreased G-actin monomer expression in DBP/ islets (scale
bar represents 34 mm; n = 19–25 islets, 5 animals; unpaired t test).
(F and G) Representative super-resolution Airyscan (140 nm lateral resolu-
tion) snapshots of glucagon granules (F), showing an 20% decrease in size
(G) (magnified images from F are shown above each bar; scale bar represents
6 mm; n = 13–15 islets, 3 to 4 animals; unpaired t test).
(H and I) Representative G-function analysis on actual and simulated glucagon
granule distribution showing that glucagon granules tend to be more clustered
in DBP+/+ (H) compared to DBP/ (I) islets (actual and simulated distribution
is inset).
(J and K) Representative images (J) and bar graph (K) showing that F-actin
levels are increased in DBP/ islets but can be restored to almost DBP+/+
levels using 0.3–1.25 mM Latrunculin B (scale bar represents 53 mm; n = 15–22
islets, 3 to 4 animals; one-way ANOVA with Dunnett’s post hoc test).
(L and M) Representative images (L) and summary bar graph (M) showing that
0.3 mM Latrunculin B rescues a cell responses to low (0.5 mM) glucose in
DBP/ islets (images have been cropped to show a single islet; scale bar
represents 25 mm; n = 11 to 12 islets, 3 to 4 animals; one-way ANOVA with
Tukey’s post hoc test).
(N) Latrunculin B (0.3 mM) rescues basal (3 mM glucose) b cell Ca2+ activity in
DBP/ islets (n = 21 to 22 islets, 5 animals; one-way ANOVAwith Tukey’s post
hoc test).
Bar graphs show scatterplot with mean ±SEM. *p < 0.05 and **p < 0.01. Latrun
B or Lat B, Latrunculin B.
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was significantly increased in islets from DBP/ animals (Fig-
ures 3T and 3U). This effect was likely associated with improved
exocytosis of the readily releasable pool of insulin granules,
because KCl-stimulated insulin secretion was significantly
higher in DBP/ versus DBP+/+ islets (Figures 3T and 3U),
despite equivalent insulin content (Figure 3V).
Thus, DBP is required for normal glucose-regulated glucagon
secretion and limits insulin secretion under high-glucose
stimulation.
DBPMediates aCell and bCell Function through F-actin
Binding
DBP is a major actin scavenger and might exert effects on a cell
size and glucagon secretion by trapping monomeric actin
(G-actin), which is needed to form polymerized actin (F-actin;
Dominguez and Holmes, 2011). To investigate DBP-actin inter-
actions, high-resolution snapshots were taken of islets stained
with either phalloidin or DNAaseI to demarcate F-actin and
G-actin, respectively. Increases in F-actin staining intensity
and fiber density were seen throughout DBP/ islets (Figures
4A–4C), rather than restricted solely to a cells. Conversely,
G-actin levels were reduced in DBP/mice, again being evident
throughout the islet (Figures 4D and 4E).
Because F-actin/G-actin ratio is important for regulated secre-
tion (Kalwat and Thurmond, 2013), glucagon granule size and
distribution were mapped in pancreatic slices using super-reso-
lution imaging. Analysis of individual granules revealed a small
but significant decrease in granule size in DBP/mice, althoughCell Reports 31, 107761, June 16, 2020 7
Figure 5. DBP Expression Is Decreased in Late-Onset and Long-
Standing Type 1 Diabetes
(A) Fluorescent immunohistochemistry showing strong expression of DBP in
the a cell compartment in human islets (inset shows a zoomed image; n = 7
control donors).
(B–E) Glucagon staining decreases slightly (B and C) in islets of donors with
early-onset (%10 years old) T1D, but this is not associated with changes in
DBP expression (B and D) or proportion of DBP+/GCG+ a cells (E) (represen-
tative images are shown; inset shows a zoomed image; n = 300 cells, 30 islets,
3 T1D donors and age-matched controls; from the Exeter biobank; Mann-
Whitney test).
(F–H) Glucagon (F and G) and DBP (F and H) expression are both decreased in
islets of donors with late-onset (R15 years old) T1D (representative images are
shown; inset shows a zoomed image; n = 400 cells, 40 islets, 4 T1D donors and
age-matched controls; Mann-Whitney test).
(I and J) a cell size (I), but not proportion of DBP+/GCG+ a cells (J), is decreased
in islets of donors with late-onset (R15 years old) T1D (n = 180 cells, 30 islets, 3
T1D donors and age-matched controls; inset shows a zoomed image; un-
paired t test).
Scale bar represents 42.5 mm. Bar graphs show scatterplot with mean ± SEM.
**p < 0.01. See also Figures S2–S4 and Table S1.
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granule number (Figures 4F and 4G). Although glucagon gran-
ules tended to be clustered in DBP+/+ a cells, they were more
diffusely scattered throughout the cytoplasm in DBP/ tissue
(Figures 4H and 4I). We note that, at the lateral resolutions
achieved here (140 nm), measurement of individual glucagon
granules (200–400 nm; Pfeifer et al., 2015) is possible. We
concede that electron microscopy would be needed to defini-
tively measure glucagon granule size and morphology, although
other issues become problematic with this technique, such as
dehydration artifacts.
Lastly, we investigated whether normal activity could be
rescued in DBP/ islets by reducing F-actin levels to DBP+/+
levels. Experiments were performed in the absence or presence
of Latrunculin B, which prevents F-actin polymerization (Spector
et al., 1983). A concentration response showed that Latrunculin
B was able to modulate F-actin within the range detected in
DBP+/+ islets (Figure 4J). Notably, by using 0.3 mM Latrunculin
B to reduce F-actin in DBP/ islets down to DBP+/+ levels (Fig-
ure 4K), we were able to partially restore both a cell and b cell
Ca2+ responses to low glucose (Figures 4L–4N).
Together, these results suggest that DBP knockout increases
availability of monomeric G-actin, which is then able to poly-
merize to form F-actin, ultimately altering granule distribution
and size, as well as a cell function.
DBP and Glucagon Expression Is Decreased in Late-
Onset and Long-Standing T1D Donors
Islet a cells persist in T1D but display reduced glucose respon-
siveness (Brissova et al., 2018; Gerich et al., 1973), which could
be associated with altered DBP expression. We therefore exam-
ined whether DBP levels changed in T1D, initially using pancre-
atic sections from the Exeter Archival Diabetes Biobank. Immu-
nohistochemistry was performed on sections from donors with
early- (%10 years old) and late-onset (R15 years old) T1D,
together with their age-matched controls. In donors without dia-
betes, DBP was highly localized to a cells (Figure 5A), as previ-
ously shown (Kodama et al., 2016; Lam et al., 2019), although
Figure 6. DBP Expression Increases with Age and Co-localizes with Glucagon in Granules
(A–C) DBP (A and B) and glucagon (A and C) expression increase with age in control donors (representative images are shown; scale bar represents 42.5 mm; n =
15–53 islets per age group, 3 early-onset and 4 late-onset T1D donors together with age-matched controls; one-way ANOVA with Tukey’s multiple comparison
test).
(D) Analysis of a published RNA-seq dataset from purified a cells (Brissova et al., 2018) shows no difference in transcript abundance for GC (encoding DBP) in
control and T1D donors. Expression levels are normalized against TBP. Each individual donor is shown. Data were obtained from GEO: GSE106148.
(E) Super-resolution images showing co-localization of DBP and glucagon within the same granule in a cells of both control and late-onset T1D donors
(representative images are shown; scale bar represents 6 mm; n = 8 cells from 8 islets, 4 late-onset T1D donors together with age-matched controls).
(F and G) The ratio of glucagon:DAPI (F) and DBP/glucagon co-localization strength (G) is lower in a cells from donors with late-onset T1D (n = 8 cells, 4 late-onset
T1D donors together with age-matched controls; unpaired t test).
(H) Glucagon granule size is decreased in a cells fromdonorswith late-onset T1D (magnified images fromE are shown above each bar; n = 160–200 granules from
4 islets, 4 late-onset T1D donors together with age-matched controls; Mann-Whitney test).
(I) Representative G-function analysis on actual and simulated glucagon granule distribution showing amore random arrangement of glucagon granules in a cells
of T1D donors (actual and simulated distribution is inset).
(J and K) Structured illumination microscopy shows DBP localized to the glucagon granule membrane (J), quantified as fluorescence intensity along a line
spanning cytoplasm-granule membrane-granule core (K) (scale bar in J: left panel represents 1.5 mm, right panel represents 0.5 mm; n = 11 line profiles, 3 donors).
Bar graphs show scatterplot with mean ± SEM. Line graphs shown mean ± SEM. **p < 0.01. TBP, TATA-box binding protein. See also Table S1.
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OPEN ACCESSwe were also able to detect very faint expression in b cells, as for
mouse (Figure S2). In sections from donors with T1D, a similar
pattern of DBP immunostaining was observed (Figure 5B).
Although a small but significant decrease in glucagon expression
was seen in islets of early-onset T1D donors (Figure 5C), this was
not accompanied by changes in DBP staining (Figure 5D) or pro-
portion of a cells immunopositive for DBP (Figure 5E).
By contrast, glucagon levels were almost 2-fold lower in islets
of late-onset T1D donors versus age-matched controls (Figures
5F and 5G), in line with previous reports of decreased a cell mass
during T1D (Bonnet-Serrano et al., 2018). These changes were
accompanied by a reduction in DBP expression (Figure 5H)
and a cell size (Figure 5I), although no differences were detected
in the number of DBP+/GCG+ cells per islet (Figure 5J). We were
able to confirm results in samples from IsletCore (Alberta) and
also show that DBP levels consistently decrease in islets of do-
nors with more long-standing T1D (Figure S3).
Immunohistochemistry of control islets showed that DBP
expression increased with age, peaking at 18–32 years and re-
maining elevated thereafter (Figures 6A and 6B). Similar results
were seen for glucagon expression (Figure 6C). Glucagon and
DBP expression values for each individual donor are provided
in Figure S4.
Granular DBP Content Decreases in Late-Onset T1D
Analysis of a published RNA sequencing (RNA-seq) dataset
(Brissova et al., 2018) revealed no differences in GC expression
in purified a cells from control and T1D donors (20–53 years; Fig-
ure 6D), suggesting that DBP might be post-transcriptionally
regulated. As such, we investigated DBP and glucagon localiza-
tionwithin human a cells using super-resolutionmicroscopy. Un-
expectedly, DBP was found to be present in glucagon granules
of control donors (Figure 6E), suggesting that DBP enters the
secretory pathway and might function in an autocrine manner.
Explaining the decrease in glucagon and DBP expression in
late-onset T1D samples, a large reduction in the number of
GCG+/DBP+ granules was detected in each a cell (Figure 6F),
accompanied by a small decrease in DBP/GCG co-localization
(Figure 6G). Glucagon granules were also smaller and more
randomly distributed in late-onset T1D a cells (Figures 6H and
6I), suggestive of changes in the actin cytoskeleton, as demon-
strated for mice.
Using structured illumination microscopy (SIM) (110 nm
lateral resolution), we were able to observe the presence of
DBP on the glucagon granule membrane (Figures 6J and 6K),
further confirming the quantitative nature of our approaches
and suggesting that DBP might act on the cell membrane
following vesicle fusion (rather than be co-secreted with the
glucagon cargo).
DISCUSSION
In the present study, we show that DBP is strongly expressed in
murine and human a cells. Loss of DBP leads to alterations in a
cell number and size, electrical activity, and glucagon release
both in vitro and in vivo. This is accompanied by changes in
d cell mass, as well as alterations in b cell function and insulin
release. Linking these findings, DBP was found to decrease10 Cell Reports 31, 107761, June 16, 2020the availability of actin monomeric subunits for assembly into
polymers. DBP expression levels were also decreased in islets
of donors with late-onset or long-standing T1D, but not in chil-
dren with early-onset disease.
Transcriptomic studies have consistently shown that Gc is
highly enriched in the mouse a cell lineage (Adriaenssens et al.,
2016; Cigliola et al., 2018; Qiu et al., 2017), similarly to data
from humans (Ackermann et al., 2016; Segerstolpe et al.,
2016). In keeping with these findings, our immunohistochemical
analyses confirmed that DBP is predominantly expressed at the
protein level in a cells in mouse as well as human (Kodama et al.,
2016; Lam et al., 2019). Careful inspection of images also de-
tected faint DBP expression in b cells, which was difficult to
appreciate due to the high intensity of the DBP signal in a cells.
Notably, DBP expression was absent in b cells in DBP/ islets,
and F-actin and G-actin were both altered across the islet. Thus,
DBP is detectable in both a cells and b cells, with large differ-
ences in expression levels apparent between the two compart-
ments. In addition, recent studies have shown that b cells in-
crease histone modification at the Gc locus in response to
high-fat feeding, with knockout of Gc protecting from b cell
dysfunction (Kuo et al., 2019). As such, DBP protein expression
in the b cell compartment is low but is likely to be upregulated un-
der conditions of metabolic stress.
Previous studies using a KOMP mouse (Gctm1.1(KOMP)Vlcg)
showed that glucagon secretion was not different between islets
from knockout (KO) animals and control littermates fed high-fat
diet (Kuo et al., 2019). It should be noted, however, that the au-
thors also included mice possessing 1 3 wild-type Gc allele as
controls (i.e., heterozygotes), which we show here is associated
with a 50% reduction in both 25(OH)D and 1,25(OH)2D concen-
trations. Therefore, we think that the discrepancies between our
studies and those of Kuo et al. (2019) likely reflect inability to
detect differences between glucagon secretion in homozygous
and heterozygous animals. Indeed, well-powered clinical chem-
istry phenotypic assays of Gctm1.1(KOMP)Vlcg mice showed signif-
icant decreases in fed blood glucose levels, which would be ex-
pected in the presence of hypoglucagonemia. Further work up of
glucagon-centric measures in Gctm1.1(KOMP)Vlcg and DBP/
mice might be interesting, comparing directly homozygous, het-
erozygous, and wild-type littermates.
Intriguingly, Na+ currents, which contribute to action potential
firing in a cells, were increased in DBP/ a cells. This was
mirrored at the level of low glucose-stimulated Ca2+ rises, which
were also increased by loss of DBP. Given that a cell function
was otherwise decreased across the board (i.e., defective
glucagon secretion, activation by low glucose, electrophysiolog-
ical identity, and Na+ channel inactivation), increases in Na+
conductance and Ca2+ spiking amplitude are likely to reflect
a maladaptive compensatory response. Alternatively, these
changes could alter glucagon/glutamate feedback at high
glucose (Caicedo, 2013), subsequently leading to blunted
glucagon secretion at low glucose. The changes in a cell function
are unlikely to be related to de-differentiation or reductions in
d cell activity, because expression of a-cell-specific transcription
factors was unaffected by loss of DBP and somatostatin has
been shown to inhibit glucagon secretion (Mandarino et al.,
1981).
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of glucagon release (Hutchens and Piston, 2015), fiber density
was increased in DBP/ animals, alongside decreases inmono-
meric G-actin content. Thus, DBP in the a cell likely scavenges
G-actin, preventing formation of F-actin polymers, which would
otherwise suppress glucagon release. At the molecular level,
F-actin has been shown to restrict basal insulin release (Kalwat
and Thurmond, 2013), as well as maximal glucagon secretion,
by acting as a physical constraint against granule exocytosis
(Hutchens and Piston, 2015; Reissaus and Piston, 2017).
Morphological evidence for this was provided in the current
study by the observation that glucagon granules were distrib-
uted more diffusely in DBP/ islets. Furthermore, granule size
was decreased, indicative of either sequestration of immature
granules or preferential release of larger, more mature granules.
Indeed, F-actin has been shown to influence granule transport
and retention through its barrier and scaffold functions (Gutie´rrez
and Villanueva, 2018). Cytoskeletal changes were also likely to
be involved in the reduction in a cell and d cell size, because as-
sembly of actin filaments from monomers is critical for cell
morphology (Pollard and Cooper, 2009).
b cells displayed F-actin-dependent increases in Ca2+ activity
at low glucose in DBP/ islets. This, however, did not translate
to elevated basal insulin release, probably because F-actin fiber
density was also increased across b cells, potentially acting as a
barrier for unregulated granule exocytosis under low glucose
conditions (Mziaut et al., 2016). Although DBP levels were
much lower in b cells compared to a cells, it could be argued
that only small amounts are required to prevent actin polymeriza-
tion, given the high binding affinity for monomeric actin (Mc Leod
et al., 1989). By contrast, lack of a cell shutoff at high glucose
would be expected to positively influence b cell activity and in-
crease glucose-stimulated insulin secretion (Svendsen et al.,
2018). An alternative mechanism might center on the decrease
in d cell number, which would be expected to decrease the tonic
negative somatostatin tone exerted on b cells (van der Meulen
et al., 2015). It should be noted that the actin barrier would not
feature under conditions of b cell stimulation, because glucose
induces dramatic actin remodeling through gelsolin (Tomas
et al., 2006), which binds actin filaments in competition with
DBP. Indeed, such cytoskeletal remodeling is likely to explain
some of the seemingly opposite effects of DBP loss on a cell
and b cell function, because the actin-scavenging properties of
DBP become relatively less important at high glucose.
Demonstrating the relevance of our studies for human dis-
ease, islets in pancreata from individuals with late-onset or
long-standing T1D consistently showed decreased DBP expres-
sion, as well as a reduction in a cell size. Super-resolution imag-
ing showed that the majority of glucagon granules in human a
cells also contained DBP, with a sharp decrease in granular
expression levels during T1D. A similar localization of DBP to
secretory granules was reported in human neutrophils, together
with release of the protein into the extracellular milieu (Kew et al.,
1993). Because the GC transcriptional machinery is present in
the a cell, the source of this DBP is likely from de novo synthesis.
It is also plausible that DBP is transported from the circulation
into a cells by megalin-mediated endocytosis, as reported in
the kidney (Nykjaer et al., 1999), and that either this process orliver production of DBP is altered during T1D. However, it is diffi-
cult to envisage how endocytosis would lead to accumulation of
DBP specifically on the membrane of glucagon granules.
Interestingly, no changes in DBP expression were found in
early-onset T1D donors. However, DBP expression was signifi-
cantly lower in young versus older control donors without T1D.
These data suggest that DBP expression and thus a cell identity
might not be fully specified until adolescence, meaning that DBP
cannot be further downregulated in early-onset T1D. Although
defects in a cell function are observed in patients with early-
onset diabetes (Siafarikas et al., 2012), this presumably stems
from DBP-independent mechanisms, which are then exacer-
bated with age as decreases in DBP become relatively more
important. Indeed, a cell dysfunction during T1D is likely caused
by multiple non-mutually exclusive mechanisms or insults, as for
b cell failure during T2D.
These data raise a number of interesting questions involving
the known role of DBP as a novel autoantigen during T1D (Ko-
dama et al., 2016). For example, does DBP only act as an auto-
antigen in late-onset T1D patients? Is the decrease in DBP
expression seen in late-onset T1D a consequence of autoanti-
gens or another unrelated mechanism? If DBP is an autoantigen
in T1D, why do a cells not die, or are the low DBP-expressing b
cells instead targeted? Could a cells confer autoimmunity on b
cells through paracrine DBP signaling? How do these findings
relate to polymorphic variants in GC, which are known to influ-
ence DBP action/levels, as well as 25(OH)D (Powe et al.,
2013)? Further systematic studies in autoantigen-positive and
negative early- and late-onset T1D donors, as well as individuals
harboringGC risk alleles, will be required to address these ques-
tions. Nonetheless, our studies suggest that, together with adop-
tion of a b-cell-like transcriptional profile (Brissova et al., 2018),
loss of DBP might contribute to the impaired glucagon secretion
reported in T1D (Brissova et al., 2018; Marchetti et al., 2000).
We acknowledge a number of limitations in the present study.
First, the animals were globally deleted for DBP, which means
that the effects of the protein specifically in a cells could not
be examined. However, DBP is highly expressed in a cells, which
validates our model. Moreover, use of DBP/ mice allowed us
to uncover a hitherto underappreciated role of DBP in regulating
b cell and d cell function, and a global deletion model would be
more reflective of studies in humans bearing homozygous dele-
tion of GC (Henderson et al., 2019). Nonetheless, it will be inter-
esting in the future to recombine animals bearing floxed alleles
with the Gcg-CreERT2 deleter line (Ackermann et al., 2017),
which would also avoid any issues with loss of DBP during crit-
ical phases of a cell development. Second, although animals
were fed a vitamin-D-sufficient diet, we cannot completely
exclude vitamin-D-dependent effects of DBP. Suggesting that
this is unlikely to be the case, a single individual harboring homo-
zygous mutations inGC did not show symptoms consistent with
vitamin D deficiency despite very low plasma 25(OH)D levels
(Henderson et al., 2019). This argues for the free hormone hy-
pothesis, where DBP acts as a major vitamin D reservoir, but
only low levels are required for biological effects (Chun et al.,
2014). Third, morphometric analyses were based upon glucagon
staining, which could lead to an underestimation of a cell size in
T1D samples, especially if the fewer detectable granules wereCell Reports 31, 107761, June 16, 2020 11
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only used samples from two biobanks, and as such, differences
in sample processing and storage could contribute to the find-
ings reported here. Fourth, although the mice did not show a
clear phenotype, further studies are warranted using in vivo
models of a cell stress, for example, glucagon receptor antago-
nism or high-fat diet (Gu et al., 2009; Merino et al., 2015), prefer-
ably using a conditional knockout. Lastly, although a causal
role for DBP in a cell dysfunction is suggested by mouse
studies, we cannot confidently assert the same in islets of human
T1D donors where autoimmunity and species differences come
into play.
In summary, we show that DBP contributes to a cell pheno-
type and glucagon secretion, with changes in expression
apparent during late-onset and long-standing T1D. The stage
is now set for investigating more widely how DBP influences islet
function and disease risk in individuals with T1D and T2D.
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Oligonucleotides
Ppia For: AAGACTGAGTGGTTGGATGG Sigma-Aldrich N/A
Ppia Rev: ATGGTGATCTTCTTGCTGGT
Pax6 For: CAGTGTCTACCAGCCAATCC Sigma-Aldrich N/A
Pax6 Rev: GCACTGTACGTGTTGGTGAG
Arx For: TTCCAGAAGACGCACTACCC Sigma-Aldrich N/A
Arx Rev: TCTGTCAGGTCCAGCCTCAT
Pou3f4 For: CCGACCAGCATTGACAAGATC Sigma-Aldrich N/A
Pou3f4 Rev: GAGGTTCGCTTCTTGCGTTT
Irx2 Thermo Fisher Scientific Taqman: Mm01340316_m1
Hhex For: CGAGACTCAGAAATACCTCTCCC Sigma-Aldrich N/A
Hhex Rev: CTGTCCAACGCATCCTTTTTG
Ghsr For: GCTCACCGTGATGGTATGGG Eurofins N/A
Ghsr Rev: CCCGATGAGACTGTAGAGCAC
Pdx1 For: ACTTAACCTAGGCGTCGCACAAGA Sigma-Aldrich N/A
Pdx1 Rev: GGCATCAGAAGCAGCCTCAAAGTT
Mafa For: CGGGAACGGTGATTGCTTAG Sigma-Aldrich N/A
Mafa Rev: GGAGGTTGGGACGCAGAA
Nkx6.1 For: GCCTGTACCCCCCATCAAG Sigma-Aldrich N/A
Nkx6.1 Rev: GTGGGTCTGGTGTGTTTTCTCTT
Ins1 For: GCTGGTGGGCATCCAGTAA Sigma-Aldrich N/A
Ins1 Rev: AATGACCTGCTTGCTGATGGT
Ins2 For: GAAGTGGAGGACCCACAAGT Sigma-Aldrich N/A
Ins2 Rev: GATCTACAATGCCACGCTTC
Gc Thermo Fisher Scientific Taqman: Mm04243540_m1
Gusb Thermo Fisher Scientific Taqman: Mm01197698_m1
Antibodies
Guinea pig anti-PDX1 Abcam Abcam Cat# ab47308; RRID:AB_777178
MAFA Bethyl Laboratories Bethyl Cat# IHC-00352; RRID:AB_1279486
Rabbit anti-insulin Cell Signaling Technology Cell Signaling Technology Cat# 3014;
RRID:AB_2126503
Guinea pig anti-insulin Abcam Abcam Cat# ab7842; RRID:AB_306130
Mouse monoclonal anti-glucagon Sigma-Aldrich Sigma-Aldrich Cat# G2654; RRID:AB_259852
Rabbit anti-glucagon Sigma-Aldrich Sigma-Aldrich Cat# SAB4501137;
RRID:AB_10761583
Mouse anti-somatostatin Thermo Fisher Scientific Thermo Fisher Scientific Cat# 14-9751-80;
RRID:AB_2572981
Rabbit anti-DBP Sigma-Aldrich Sigma-Aldrich Cat# HPA019855;
RRID:AB_1849545
Mouse anti-PCNA Cell Signaling Technology Cell Signaling Technology Cat# 2586;
RRID:AB_2160343
Guinea pig anti-insulin Agilent Agilent Cat# A0564; RRID:AB_10013624
Mouse anti-glucagon Abcam Abcam Cat# ab10988; RRID:AB_297642
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Goat anti-rabbit Alexa Fluor 488 Thermo Fisher Scientific Thermo Fisher Scientific Cat# R37116;
RRID:AB_2556544
Goat anti-guinea pig Alexa Fluor 488 Thermo Fisher Scientific Thermo Fisher Scientific Cat# A-11073;
RRID:AB_2534117
Goat anti-mouse Alexa Fluor 488 Thermo Fisher Scientific Thermo Fisher Scientific Cat# A-11029;
RRID:AB_138404
Goat anti-guinea pig Alexa Fluor 568 Thermo Fisher Scientific Thermo Fisher Scientific Cat# A-11075;
RRID:AB_2534119
Goat anti-mouse Alexa Fluor 555 Thermo Fisher Scientific Thermo Fisher Scientific Cat# A-11075;
RRID:AB_2534119
Goat anti-rabbit Alexa Fluor 633 Thermo Fisher Scientific Thermo Fisher Scientific Cat# A-21052;
RRID:AB_2535719
Goat anti-guinea pig Alexa Fluor 647 Thermo Fisher Scientific Thermo Fisher Scientific Cat# A-21450;
RRID:AB_2735091
Chemicals, Peptides, and Recombinant Proteins
PowerUp SYBR Green Master Mix Thermo Fisher Scientific Thermo Fisher Scientific Cat# A25742
TaqMan Fast Advanced Master Mix Thermo Fisher Scientific Thermo Fisher Scientific Cat# 4444556
SERVA NB8; amsbio Cat# 17456.01 amsbio amsbio Cat# 17456.01
VECTASHIELD HardSet with DAPI Vector Laboratories Vector Laboratories Cat# H-1500
Fura2-AM Hello Bio HelloBio HB0780-1mg
Phalloidin-488 Abcam Abcam Cat# ab176753
Latrunculin B Abcam Abcam Cat# ab144291
DNaseI-594 Invitrogen Invitrogen Cat# D12372
Critical Commercial Assays
Ultrasensitive glucagon HTRF assay Cisbio Cisbio Cat# 62CGLPEG
Ultrasensitive insulin HTRF assay Cisbio Cisbio Cat# 62IN2PEG
Glucagon ELISA - 10 mL Mercodia Mercodia Cat#10-1281-01
Experimental Models: Organisms/Strains
DBP/ mice Prof Nancy Cooke, University
of Pennsylvania
(Safadi et al., 1999)
Human pancreas sections Exeter Archival Diabetes
Biobank and Alberta Diabetes
Institute IsletCore
https://foulis.vub.ac.be/
https://www.epicore.ualberta.ca/
isletcore/Default
https://iidp.coh.org
Software and algorithms
Prism 7 GraphPad software N/A
MATLAB Mathworks N/A
R-Studio R-Project N/A
Igor Pro WaveMetrics N/A
Patchmaster HEKA Electronics N/A
Other
Contour XT glucometer N/A Bayer
Zeiss LSM780 meta-confocal N/A Carl Zeiss Microscopy
Zeiss LSM880 meta-confocal N/A Carl Zeiss Microscopy
Crest spinning disk N/A Cairn Research
Nikon N-SIM S N/A Nikon Instruments
Applied Biosystems 7500/7900HT Real-Time
PCR System
N/A Applied Biosystems
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Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David J.
Hodson (d.hodson@bham.ac.uk).
Materials availability
This study did not generate new unique reagents.
Data and code availability
This study did not generate any unique datasets or code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse models
DBP/ mice were generated using a PGK-promoter/neomycin cassette to disrupt exon 5 of the mouse Gc gene, as described (Sa-
fadi et al., 1999). We used these animals rather than the KOMP repository strain (Gctm1.1(KOMP)Vlcg; MGI:5577272), since they have
been subjected to thorough phenotypic validation and show loss of serum DBP protein, as well as 25(OH)[3H]D3 binding (Safadi
et al., 1999). DBP/ mice were backcrossed for 10 generations onto a C57BL/6J background at the University California Los
Angeles, before re-derivation of embryos into the University of Birmingham facility using C57BL/6J recipients. The line was refreshed
every few months by backcrossing with non-sibling C57BL/6J purchased from Charles River UK. Animals were group-housed in a
specific-pathogen free facility with ad lib access to regular chow (which contains 1000 U/kg cholecalciferol) and water. All studies
were performed with 6-15 week-old male and female animals, and regulated by the Animals (Scientific Procedures) Act 1986 of
the UK. Littermates were allocated to treatment groups in a randomized manner to ensure that all states were represented in the
different experiment arms. Investigators were blinded to animal identity. Approval was granted by the University of Birmingham’s
Animal Welfare and Ethical Review Body.
Human donors
Formalin-fixed paraffin-embedded pancreas sections were obtained from the Exeter Archival Diabetes Biobank (EADB) (https://
foulis.vub.ac.be/) or the Alberta Diabetes Institute IsletCore (quality control and phenotyping data is available for each preparation
via https://www.epicore.ualberta.ca/isletcore/Default and https://iidp.coh.org). All EADB samples were used with ethical permission
from the West of Scotland Research Ethics Committee (ref: 15/WS/0258). Procurement of human pancreases was approved by the
Human Research Ethics Board (Pro00013094; Pro00001754) at the University of Alberta and all families of organ donors provided
written informed consent. Studies with human tissue were approved by the University of Birmingham Ethics Committee, as well
as the National Research Ethics Committee (REC reference 16/NE/0107, Newcastle and North Tyneside, UK). Donor age, sex
and BMI are reported in Table S1.
METHOD DETAILS
Glucose, insulin and pyruvate tolerance testing
Mice were fasted for 4-5 hr before intraperitoneal injection of either 2g/kg sterile-filtered D-glucose, 0.75 U/kg insulin or 2g/kg pyru-
vate, and tail vein bleed at 0, 15, 30, 60, 90 and 120 mins. Glucose levels were measured using a Contour XT glucometer (Bayer). For
glucagon measures, animals were fasted for 4 hr, insulin injected at 0 min, and blood collected at 30 min. Non-responsive animals
were excluded from analysis for both genotypes. Serum glucagon was assayed using a glucagon enzyme-linked immunosorbent
assay (ELISA) kit (Mercodia Cat# 10-1281-01) (10 ml serum/sample used).
Vitamin D measures
Animals were bled under terminal anesthesia, before measurement of circulating concentrations of 25(OH)D and hormonal
1,25(OH)2D using liquid chromatography-tandem mass spectrometry methods, as described previously (Tamblyn et al., 2017).
Islet isolation and culture
Animals were euthanized by cervical dislocation, before isolation of islets using collagenase digestion (1 mg/ml, SERVA NB8; amsbio
Cat# 17456.01) and Histopaque or Ficoll-Paque gradient separation. Islets were maintained at 37C and 5% CO2 in RPMI medium
containing 10% FCS, 100 units/mL penicillin, and 100 mg/mL streptomycin.
Gene expression
Relative mRNA abundance was determined using an Applied Biosystems 7500 or 7900HT instrument and PowerUp SYBR Green
Master Mix (Thermo Fisher Scientific Cat# A25742) or TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific Cat#Cell Reports 31, 107761, June 16, 2020 e3
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see Key Resources Table.
Glucagon and insulin assays
Batches of 10 islets were pre-incubated in either 10mMor 3mMglucose for 1 hour at 37C in buffer containing (in mmol/L) 120 NaCl,
4.8 KCl, 24 NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 CaCl2, 1.2 MgCl2 + 0.1% BSA. For glucagon secretion, islets were incubated in
10 mM, 0.5 mM or 0.5 mM glucose + 5 mM epinephrine for 1 hour at 37C. Insulin was measured similarly, but using batches of
10 islets sequentially incubated in 3 mM glucose, 17 mM glucose and 17 mM glucose + 10 mM KCl for 30 minutes at 37C. Total
glucagon and insulin were extracted from islets lysed in acid ethanol. Glucagon and insulin concentrations weremeasured using spe-
cific ultrasensitive HTRF assay (glucagon; Cisbio Cat# 62CGLPEG) (insulin; Cisbio Cat# 62IN2PEG). In all cases, values are normal-
ized against total glucagon/insulin for each individual experiment to account for differences in a-cell/b-cell proportion with treatment
and islet size (Henquin, 2019).
Immunostaining of mouse tissue
Pancreata were fixed in 10% formalin overnight, before dehydration and wax embedding. Sections were blocked with PBS-T + 1%
BSA for 1 hour and incubated with primary antibodies overnight at 4C. Following washing in PBS-T + 0.1% BSA, secondary anti-
bodies were applied for 2 hours at room temperature. Primary antibodies were rabbit anti-insulin 1:500 (Cell Signaling Technology
Cat# 3014, RRID:AB_2126503), guinea pig anti-insulin 1:50 (Abcam Cat# ab7842, RRID:AB_306130), mouse monoclonal anti-
glucagon 1:2000 (Sigma-Aldrich Cat# G2654, RRID:AB_259852), rabbit anti-glucagon 1:100 (Sigma-Aldrich Cat# SAB4501137,
RRID:AB_10761583), mouse anti-somatostatin 1:1000 (Thermo Fisher Scientific Cat#14-9751-80, RRID:AB_2572981), rabbit anti-
DBP 1:1000 (Sigma-Aldrich Cat# HPA019855, RRID:AB_1849545), guinea pig anti-PDX1 1:200 (Abcam Cat# ab47308,
RRID:AB_777178), rabbit anti-MafA 1:1000 (Bethyl laboratories Cat# IHC-00352, RRID:AB_1279486), and mouse anti-PCNA
1:500 (Cell Signaling Technology Cat# 2586, RRID:AB_2160343). We note that the rabbit anti-DBP antibody (Sigma-Aldrich Cat#
HPA019855, RRID:AB_1849545) was developed and validated by the Human Protein Atlas project, passing multiple quality controls
(https://www.proteinatlas.org/ENSG00000145321-GC/antibody#protein_array). Specificity was further confirmed here using
DBP/ tissue in which antibody staining was absent using non-fluorescent immunohistochemistry.
Secondary antibodies were goat anti-rabbit Alexa Fluor 633 (Thermo Fisher Scientific Cat# A-21052, RRID:AB_2535719), goat
anti-rabbit Alexa Fluor 488 (Thermo Fisher Scientific Cat# R37116, RRID:AB_2556544), goat anti-guinea pig Alexa Fluor 488 (Thermo
Fisher Scientific Cat# A-11073, RRID:AB_2534117), goat anti-mouse Alexa Fluor 488 (Thermo Fisher Scientific Cat# A-11029,
RRID:AB_138404), goat anti-guinea pig Alexa Fluor 568 (Thermo Fisher Scientific Cat# A-11075, RRID:AB_2534119), all at
1:1000. Fixed islets were incubated with Phalloidin-488 (Abcam Cat# ab176753) and DNaseI-594 (Invitrogen Cat# D12372) for 2
hours at room temperature to stain F-actin and G-actin.
Images were captured using either Zeiss LSM780 or LSM880 meta-confocal microscopes, the latter equipped with an Airyscan
super-resolution module. Excitation was delivered at l = 488 nm, l = 568 and l = 633 nm for Alexa Fluor 488, Alexa Fluor 568
and Alexa Fluor 633, respectively. Emitted signals were detected using a GaAsP PMT detector at l = 498–559, nm l = 568–629
and l = 633–735 nm for Alexa Fluor 488, Alexa Fluor 568 and Alexa Fluor 633, respectively. Super-resolution images were subjected
to online deconvolution processing using Zen Black (Zeiss Microscopy).
Immunostaining of human tissue
Tissuewas obtained from individuals with T1D and their age-matched controls. Donor details are provided in Table S1. Sampleswere
dewaxed and rehydrated before antigen retrieval and blocking with 5% normal goat serum. Primary antibodies were guinea pig anti-
insulin 1:700 (Agilent Cat# A0564, RRID:AB_10013624), mouse anti-glucagon 1:2000 (Abcam Cat# ab10988, RRID:AB_297642) or
mouse monoclonal anti-glucagon 1:2000 (Sigma-Aldrich Cat# G2654, RRID:AB_259852), and rabbit anti-DBP 1:500 (Sigma-Aldrich
Cat# HPA019855, RRID:AB_1849545). Secondary antibodies were goat anti-guinea pig Alexa Fluor 647 (Thermo Fisher Scientific
Cat# A-21450, RRID:AB_2735091), goat anti-mouse Alexa Fluor 555 (Thermo Fisher Scientific Cat# A-11075, RRID:AB_2534119),
and goat anti-rabbit Alexa Fluor 488 at 1:400 (Thermo Fisher Scientific Cat# R37116, RRID:AB_2556544).
Images were captured using Zeiss LSM780 and LSM880 meta-confocal microscopes, as above. Excitation was delivered at l =
488 nm, l = 568 nm and l = 633 nm for Alexa Fluor 488, Alexa Fluor 555 and Alexa Fluor 647 nm, respectively. Emitted signals were
detected using a GaAsP PMT detector at l = 498–561 nm, l = 564–617 nm and l = 641–691 nm for Alexa Fluor 488, Alexa Fluor 555
and Alexa Fluor 647 nm, respectively.
Structured Illumination Microscopy (SIM) was performed using a Nikon N-SIM S microscope, equipped with an SR HP Apo TIRF
100x 1.49NA/oil immersion objective andORCA-Flash 4.0 sCMOScamera. Excitationwas delivered at l= 488 nmand l= 568 nm for
Alexa Fluor 488 and Alexa Fluor 555 nm, respectively. Emitted signals were detected at l = 500-550 nm and l = 570-640 nm for Alexa
Fluor 488 and Alexa Fluor 555, respectively.
Analysis of a-cell and b-cell mass
Pancreatic sections for determination of a-cell and b-cell mass were stained as above, before scanning and digitization using a Zeiss
Axio Scan.Z1. Excitation was delivered at l = 453-485 nm and l = 590-650 nm for Alexa Fluor 488 and Alexa Fluor 647, respectively.e4 Cell Reports 31, 107761, June 16, 2020
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respectively. Overall, 408 separate images were captured for each pancreas section using a 20 x / 0.8 NA objective, before compi-
lation into a single image using Zen lite 2012.
Ca2+ imaging
Islets were loaded with Fura2 (HelloBio HB0780-1mg) before imaging using a Crest X-Light spinning disk system coupled to a Nikon
Ti-E base and 10 x / 0.4 air objective. Excitation was delivered at l = 340 nm and l = 385 nm using a FuraLED system, with emitted
signals detected at l = 470–550 nm. Traces were presented as the emission ratio at 340 nm and 385 nm (i.e., 340/385). HEPES-bi-
carbonate buffer was used, containing (in mmol/L) 120 NaCl, 4.8 KCl, 24 NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 CaCl2, 1.2MgCl2, and
0.5–17 D-glucose.
Electrophysiology
Whole-cell currents were recorded in intact islets using the standard whole-cell configuration, as previously described (Briant et al.,
2018). Measurements were performed using an EPC-10 patch-clamp amplifier and Patchmaster software (HEKA Electronics). Cur-
rentswere filtered at 2.9 kHz and digitized atmore than 10 kHz. Currents were compensated for capacitive transients and leak current
subtraction was conducted. The extracellular solution consisted of (in mmol/L) 138 NaCl, 5.6 KCl, 1.2 MgCl2, 5 HEPES (pH 7.4 with
NaOH), 2.6 CaCl2 and 1 D-glucose. The intracellular solution contained (in mmol/L) 125 KCl, 1 CaCl2, 1 MgCl2, 5 HEPES, 3 MgATP
and 10 EGTA (KOH buffered). Recordings with an access resistance of < 50 mU were used for analysis in MATLAB. The logistic
regression model identifying cell type was implemented in MATLAB, as previously described (Briant et al., 2017).
QUANTIFICATION AND STATISTICAL ANALYSIS
Image analysis
F-actin, G-actin, glucagon and DBP expression levels were analyzed using integrated density (area x mean fluorescence intensity),
which accounts for the influence of cell size on fluorophore emission intensity for a given pixel (i.e., intensity of n fluorescent mole-
cules will increase as a function of area-1). Corrected total cell fluorescence (CTCF) was then calculated as follows: integrated density
– (area of selected cell x mean background fluorescence) (Gavet and Pines, 2010). Quantification of a-cell, b-cell and d-cell area and
number was performed on binarized images using ImageJ (NIH) and Threshold, Nucleus Counter and Particle Analysis plugins.
Glucagon granule distribution was analyzed using the G-function, which measures the distance from any position to the nearest
object of interest compared to a random distribution of the samemeasured objects (FIJI Spatial Statistic 2D/3D plugin) (Andrey et al.,
2010). A left shift away from the mean ± 95% confidence intervals indicates a less random or more clustered organization.
Linear adjustments to brightness and contrast were applied to representative images, with intensity values maintained between
samples to allow accurate cross-comparison. For super-resolution images, the following FIJI look-up-tables were used: NanoJ-
Orange, cyan and magenta.
Statistical analysis
Statistical details of experiments can be found in the figure legends, No data were excluded unless the cells displayed a clear non-
physiological state (i.e., impaired viability), and all individual data points are reported in the figures. The measurement unit (n number)
is animal, batch of islets or donor, with experiments replicated independently at least three times.
Data normality was assessed using D’Agostino-Pearson test. Unpaired/paired Students t test or Mann-Whitney test were used for
pairwise comparisons (two-sided). Multiple interactions were determined using one-way or two-way ANOVA followed by Tukey’s,
Dunnett’s, Bonferonni’s or Sidak’s post hoc tests (accounting for degrees of freedom). Analyses were conducted using GraphPad
Prism or Microsoft Excel software. Data are presented as mean ± SEM or SD, with individual datapoints shown where practicable.Cell Reports 31, 107761, June 16, 2020 e5
